Amneal Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amneal Pharmaceuticals, Inc.
Stressing the need for vertical integration to be a successful biosimilars developer in the long run, Amneal co-CEO Chirag Patel has set out the firm’s future strategy in the area – including aiming to be quicker to market with future launches – as Amneal proves itself against rival biosimilars players in the US market.
Amid upheaval for leading industry players Sandoz, Teva and Viatris, Amneal sees room to grow both in its home market and internationally, according to co-CEO Chirag Patel.
As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.
Amneal has delivered on promises that it would soon finalize a European partnership by announcing a long-term licensing collaboration with Finnish firm Orion that will also cover Australia and New Zealand.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.